Publications by authors named "Marlise P de Roos"
Article Synopsis
- After recovering from COVID-19 pneumonia, many hospitalized patients experienced reduced diffusion capacity (DLCO), particularly noticeable three months post-discharge; this study tracked 317 survivors over 24 months.
- Patients were categorized by illness severity: moderate, severe, and critical, with critical cases showing the most significant DLCO impairment at three months.
- Despite overall improvements in DLCO across all patient groups by 24 months, a significant portion—65%—still had reduced DLCO (<80%), indicating that while recovery occurred, it was incomplete for most.
Objectives: A decrease of both diffusion capacity (DLCO) and Quality of Life (QoL) was reported after discharge in hospitalized COVID-19 pneumonia survivors. We studied three and 6 month outcomes in hospitalized and non-hospitalized patients.
Methods: COVID-19 pneumonia survivors ( = 317) were categorized into non-hospitalized "moderate" cases ( = 59), hospitalized "severe" cases ( = 180) and ICU-admitted "critical" cases ( = 39).
Purpose: To determine the prevalence and spectrum of incidental findings (IFs) identified in patients undergoing chest CT as a primary triage tool for COVID-19.
Methods: In this study 232 patients were triaged in our COVID-19 Screening Unit by means of a chest CT (March 25-April 23, 2020). Original radiology reports were evaluated retrospectively for the description of IFs, which were defined as any finding in the report not related to the purpose of the scan.
Background: In the coronavirus disease 2019 (COVID-19) pandemic, rapid clinical triage is crucial to determine which patients need hospitalisation. We hypothesised that chest computed tomography (CT) and alveolar-arterial oxygen tension ratio (A-a) gradient may be useful to triage these patients, since they reflect the severity of the pneumonia-associated ventilation/perfusion abnormalities.
Methods: A retrospective analysis was performed in 235 consecutive patients suspected for COVID-19.
Background: Percutaneous absorption of topically applied 0.05% clobetasol propionate (CLO) can be assessed indirectly by measuring cortisol levels. A direct way is to measure systemic levels of topically applied CLO.
View Article and Find Full Text PDFLiquid chromatography-tandem mass spectrometric assay for clobetasol propionate in human serum from patients with atopic dermatitis.
J Chromatogr B Analyt Technol Biomed Life Sci
August 2010
A bioanalytical assay for the topical corticosteroid clobetasol propionate was developed and validated. For the quantitative assay 0.5 ml human serum samples, supplemented with clobetasone butyrate as internal standard, were extracted with hexane-ether.
View Article and Find Full Text PDF